Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver

Maha M Shouman1, Rania M Abdelsalam2,3, Mahmoud M Tawfick4

  • 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern Sciences and Arts University (MSA), Giza, Egypt.

Insights

Antisense TF oligodeoxynucleotides (TFAS) effectively treated liver fibrosis in rats by suppressing tissue factor (TF) gene expression. TFAS also reduced inflammation and fibrotic markers, offering a new therapeutic strategy for liver fibrosis.

Area of Science:

  • Hepatology
  • Pharmacology
  • Molecular Biology

Background:

  • Tissue factor (TF) plays a role in non-coagulant pathways, including inflammation and fibrogenesis.
  • Coagulation and inflammation are interconnected in liver fibrosis, involving protease-activated receptor 1 (PAR1) and toll-like receptor 4 (TLR4).
  • Antisense oligodeoxynucleotides are effective gene expression modulators.

Purpose of the Study:

  • To evaluate antisense TF oligodeoxynucleotides (TFAS) for treating liver fibrosis by suppressing TF gene expression.
  • To investigate the potential crosslink between TF, PAR1, and TLR4 in liver fibrogenesis.

Main Methods:

  • Liver fibrosis was induced in rats using N-diethyl nitrosamine (DEN) and carbon tetrachloride (CCl4).
  • TF expression was blocked using TFAS injections (2.8 mg/kg) weekly for 6 weeks.
  • Changes in liver enzymes, histopathology, α-SMA, TGF-1β, TNF-α, hydroxyproline, collagen, PAR1, and TLR4 were assessed.

Main Results:

  • TFAS treatment significantly restored liver enzymes and improved histopathological features.
  • TFAS administration decreased elevated levels of α-SMA, TGF-1β, TNF-α, hydroxyproline, and collagen.
  • TFAS reduced the expression of PAR1 and TLR4 induced by liver fibrosis.

Conclusions:

  • Blocking TF expression with TFAS ameliorated inflammatory and fibrotic changes in CCl4+DEN-induced liver injury.
  • A potential crosslink between TF, PAR1, and TLR4 in liver fibrogenesis was identified.
  • Targeting TF expression presents a potential therapeutic strategy for liver fibrosis recovery.